

Supplementary Materials

Supplementary Table 1. Sensitivity analysis restricting cohort to patients treated post-2009, N=342*

Sociodemographic Characteristics	Multivariable Analyses of Outcome			
	Event-Free Survival		Overall Survival	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Neighborhood-poverty No (Q2-4: >\$35,916) Yes (Q1:<=\$35,916)	1.00 (Ref) 1.15 (0.76-1.74)	.50	1.00 (Ref) 1.26 (0.75-2.12)	.38
Household-Poverty No Yes	1.00 (Ref) 1.94 (1.31-2.88)	<.001	1.00 (Ref) 3.17 (1.84-5.46)	<.001
Ethnicity Non-Hispanic Hispanic	1.00 (Ref) 1.12 (0.72-1.75)	.61	1.00 (Ref) 1.50 (0.77-2.92)	.23
Tumor and Treatment Characteristics				
INSS Stage 2B/3/4S Stage 4 Unknown Stage	1.00 (Ref) 1.39 (0.76-2.55) 1.90 (0.74-4.85)	.29 .18	1.00 (Ref) 1.17 (0.41-3.34) 2.04 (0.47-8.85)	.77 .34
Tumor <i>MYCN</i> Not amplified Amplified Unknown	1.00 (Ref) 0.74 (0.48-1.16) 1 (0.52-1.92)	.19 1.0	1.00 (Ref) 0.97 (0.46-2.07) 1.37 (0.54-3.46)	.94 .51
End-induction disease response CR VGPR PR	1.00 (Ref) 1.61 (0.97-2.67) 1.43 (0.75-2.76)	.07 .28	1.00 (Ref) 2.63 (1.02-6.76) 2.52 (1.36-4.65)	.003 .045

* Results of multivariable analyses of EFS and OS from time of trial enrollment adjusting for ethnicity, insurance, INSS stage, disease response, *MYCN* and hospital clustering.

Supplementary Table 2. Sensitivity analysis censoring analytic cohort at 2-years, N=371*

	Multivariable Analyses of Outcome			
	Event-Free Survival		Overall Survival	
Sociodemographic Characteristics	HR (95% CI)	P-value	HR (95% CI)	P-value
Neighborhood-poverty				
No (Q2-4: >\$35,916)	1.00 (Ref)		1.00 (Ref)	
Yes (Q1:<=\$35,916)	1.16 (0.76-1.77)	.50	1.43 (0.89-2.31)	.14
Household-Poverty				
No	1.00 (Ref)		1.00 (Ref)	
Yes	1.91 (1.27-2.89)	.002	2.78 (1.54-5.00)	<.001
Ethnicity				
Non-Hispanic	1.00 (Ref)		1.00 (Ref)	
Hispanic	1.31 (0.84-2.03)	.23	1.93 (0.97-3.85)	.06
Tumor and Treatment Characteristics				
INSS Stage				
2B/3/4S	1.00 (Ref)	0.04	1.00 (Ref)	
Stage 4	2.16 (1.05-4.42)	.04	0.94 (0.32-2.71)	.90
Unknown Stage	4.45 (1.09-18.15)		2.81 (0.51-15.6)	.24
Tumor <i>MYCN</i>				
Not amplified	1.00 (Ref)		1.00 (Ref)	
Amplified	0.90 (0.63-1.29)	.58	1.10 (0.56-2.15)	.78
Unknown	0.73 (0.26-2.03)	.54	0.99 (0.24-4.11)	.99
End-induction disease response				
CR	1.00 (Ref)		1.00 (Ref)	
VGPR	1.69 (1.01-2.84)	.047	2.51 (1.16-5.42)	.02
PR	1.4 (0.71-2.77)	.33	2.95 (1.24-7.02)	.02

* Results of multivariable analyses of EFS and OS from time of trial enrollment adjusting for ethnicity, insurance, INSS stage, disease response, *MYCN* and hospital clustering.

Supplementary Table 3. Sensitivity analysis expanding cohort to include N=14 patients with missing end-induction disease status and assigning them VGPR disease status, N=385*

Sociodemographic Characteristics	Multivariable Analyses of Outcome			
	Event-Free Survival		Overall Survival	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Neighborhood-poverty No (Q2-4: >\$35,916) Yes (Q1:<=\$35,916)	1.00 (Ref) 1.11 (0.76-1.64)	.59	1.00 (Ref) 1.20 (0.75-1.90)	.45
Household-Poverty No Yes	1.00 (Ref) 1.96 (1.35-2.84)	<.001	1.00 (Ref) 3.06 (1.88-4.97)	<.001
Ethnicity Non-Hispanic Hispanic	1.00 (Ref) 1.25 (0.82-1.89)	.30	1.00 (Ref) 1.55 (0.86-2.79)	.15
Tumor and Treatment Characteristics				
INSS Stage 2B/3/4S Stage 4 Unknown Stage	1.00 (Ref) 1.42 (0.71-2.85) 1.91 (0.63-5.77)	.32 .25	1.00 (Ref) 1.83 (0.75-4.46) 3.54 (0.90-13.97)	.19 .07
Tumor <i>MYCN</i> Not amplified Amplified Unknown	1.00 (Ref) 0.73 (0.51-1.05) 0.97 (0.50-1.88)	.73 .97	1.00 (Ref) 0.93 (0.50-1.72) 1.01 (0.43-2.36)	.81 .99
End-induction disease response CR VGPR PR	1.00 (Ref) 1.78 (1.14-2.78) 1.46 (0.73-2.90)	.01 .28	1.00 (Ref) 1.99 (1.09-3.64) 2.21 (0.89-5.52)	.03 .09

* Results of multivariable analyses of EFS and OS from time of trial enrollment adjusting for ethnicity, insurance, INSS stage, disease response, *MYCN* and hospital clustering.

Supplementary Table 4. Sensitivity analysis expanding cohort to include N=14 patients with missing end-induction disease status and assigning them PR disease status, N=385*

	Multivariable Analyses of Outcome				
	Event-Free Survival		Overall Survival		
Sociodemographic Characteristics	HR (95% CI)	P-value	HR (95% CI)	P-value	
Neighborhood-poverty	No (Q2-4: >\$35,916) Yes (Q1: <=\$35,916)	1.00 (Ref) 1.12 (0.77-1.63)	.55	1.00 (Ref) 1.21 (0.77-1.91)	.41
Household-Poverty	No Yes	1.00 (Ref) 1.97 (1.35-2.86)	<.001	1.00 (Ref) 3.01 (1.86-4.88)	<.001
Ethnicity	Non-Hispanic Hispanic	1.00 (Ref) 1.22 (0.82-1.82)	.32	1.00 (Ref) 1.54 (0.85-2.78)	.15
Tumor and Treatment Characteristics					
INSS Stage	2B/3/4S Stage 4 Unknown Stage	1.00 (Ref) 1.41 (0.70-2.84) 1.96 (0.64-6.00)	.34 .24	1.00 (Ref) 1.85 (0.76-4.50) 3.69 (0.92-14.82)	.18 .07
Tumor <i>MYCN</i>	Not amplified Amplified Unknown	1.00 (Ref) 0.75 (0.53-1.07) 0.95 (0.49-1.86)	.12 .88	1.00 (Ref) 0.95 (0.50-1.78) 1.00 (0.43-2.32)	.86 1.0
End-induction disease response	CR VGPR PR	1.00 (Ref) 1.59 (0.96-2.64) 1.67 (0.93-2.99)	.07 .08	1.00 (Ref) 1.87 (0.97-3.60) 2.28 (0.99-5.26)	.06 .05

*Results of multivariable analyses of EFS and OS adjusting for ethnicity, insurance, INSS stage, disease response, *MYCN* and hospital clustering.

Supplementary Table 5. Sensitivity analysis recategorizing the N=55 patients in the analytic cohort with unknown INSS Stage to Stage 4 disease, N=371*

	Multivariable Analyses of Outcome			
	Event-Free Survival		Overall Survival	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Sociodemographic Characteristics				
Neighborhood-poverty				
No (Q2-4: >\$35,916)	1.00 (Ref)		1.00 (Ref)	
Yes (Q1:<=\$35,916)	1.13 (0.78-1.63)	.53	1.14 (0.73-1.78)	.56
Household-Poverty				
No	1.00 (Ref)		1.00 (Ref)	
Yes	1.88 (1.26-2.79)	.002	2.68 (1.54-4.68)	<.001
Ethnicity				
Non-Hispanic	1.00 (Ref)		1.00 (Ref)	
Hispanic	1.21 (0.80-1.84)	.37	1.70 (0.92-3.15)	.09
Tumor and Treatment Characteristics				
INSS Stage				
2B/3/4S	1.00 (Ref)		1.00 (Ref)	
Stage 4	1.55 (0.85-2.80)	.15	1.56 (0.56-4.33)	.39
Tumor <i>MYCN</i>				
Not amplified	1.00 (Ref)		1.00 (Ref)	
Amplified	0.77 (0.54-1.09)	.14	1.0 (0.56-1.80)	1.0
Unknown	1.20 (0.72-2.00)	.49	1.51 (0.75-3.03)	.24
End-induction disease response				
CR	1.00 (Ref)		1.00 (Ref)	
VGPR	1.61 (0.95-2.75)	.08	1.92 (1.02-3.61)	.04
PR	1.46 (0.74-2.90)	.27	2.24 (0.95-5.29)	.07

* Results of multivariable analyses of EFS and OS adjusting for ethnicity, insurance, INSS stage, disease response, *MYCN* and hospital clustering.